ANAB

Imsolimab (anti-IL-36R) (ANB019)

Palmoplantar Pustulosis

Stage (next event)

Expected Date

Phase 2 Top-Line Data

Q1 2021

Catalyst Info & Data Links

TITLE: Imsolimab (anti-IL-36R) for Palmoplantar Pustulosis Phase 2 Top-Line Data 

  • Clinical Trial (NCT03633396) A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis (PPP)


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 Top-Line Data 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q1 2021


PRIOR DATA/EVENTS

PRESS RELEASES

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon